Perrigo Co. Hits New 52-Week Low at $20.95 Amid Financial Struggles

Perrigo Co. Plc, a small-cap player in the Pharmaceuticals & Biotechnology sector, has reached a new 52-week low of USD 20.95 as of September 18, 2025. This marks a significant decline for the company, which has seen its stock price drop by 21.57% over the past year, contrasting sharply with the S&P 500's performance of 17.14% during the same period.
The company's financial metrics reveal a challenging landscape. With a market capitalization of USD 3,072 million, Perrigo is currently operating at a loss, reflected in its negative price-to-earnings ratio. The company has reported a net profit loss of USD 67.46 million over the past nine months, a staggering decline of 202.37%. Additionally, its pre-tax profit for the latest quarter fell by 90.52%, indicating ongoing difficulties in maintaining profitability.

Perrigo's debt-to-equity ratio stands at 0.72, and its return on equity is relatively low at 0.37%. The stock's price-to-book ratio of 0.69 suggests that it is trading below its book value. With raw material costs increasing by 7.52% year-over-year, the company faces additional pressures that may impact its financial stability moving forward.